Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.24), $0.26 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $200.3 million versus the consensus estimate of $205.21 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $835-845 million, versus the consensus of $854.12 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.